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Abstract  
Background: The effects of novel biocompatible peritoneal dialysis (PD) solutions on human 
peritoneal membrane pathology have yet to be determined. Quantitative evaluation of human 
peritoneal biopsy specimens may reveal the effects of the new solutions on peritoneal 
membrane pathology. 
Methods: Peritoneal specimens from 24 PD patients being treated with either acidic solution 
containing high glucose degradation products [GDPs (n = 12)] or neutral solution with low 
GDPs (n = 12) were investigated at the end of PD. As controls, pre-PD peritoneal specimens, 
obtained from 13 patients at PD catheter insertion, were also investigated. The extent of 
peritoneal fibrosis, vascular sclerosis, and advanced glycation end-product (AGE) 
accumulation were evaluated by quantitative or semi-quantitative methods. The average 
densities of CD31-positive vessels and podoplanin-positive lymphatic vessels were also 
determined. 
Results: Peritoneal membrane fibrosis, vascular sclerosis, and AGE accumulation were 
significantly suppressed in the neutral group compared with the acidic group. The neutral 
group also showed lower peritoneal equilibration test scores and preserved ultrafiltration 
volume. The density of blood capillaries, but not of lymphatic capillaries, was significantly 
increased in the neutral group compared with the acidic and pre-PD groups. 
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Conclusions: Neutral solutions with low GDPs are associated with less peritoneal membrane 
fibrosis and vascular sclerosis through suppression of AGE accumulation. 
However, contrary to expectation, blood capillary density was increased in the neutral group. 
The altered contents of the new PD solutions modified peritoneal membrane morphology and 
function in patients undergoing PD. 
Key words: AGE, angiogenesis; biocompatible solution; GDP; peritoneal dialysis; peritoneal 
fibrosis; vascular sclerosis. 
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Introduction 
Peritoneal dialysis (PD) solution should not contain bioincompatible elements such as high 
glucose, low pH, and glucose degradation products (GDPs) (1,2). Those bioincompatible 
elements promote peritoneal fibrosis, hyalinizing vasculopathy, deposition of advanced 
glycation end-products (AGEs), and angiogenesis (3,4), which in turn lead to membrane 
hyperpermeability and reduced ultrafiltration capacity because of the involvement of several 
factors, including transforming growth factor-β, vascular endothelial growth factor, 
aquaporin-1, and endothelial nitric oxide synthase (5–8). 
Recently, biocompatible PD solutions have been developed to prevent PD-related peritoneal 
damage and potentially to prolong the duration of PD treatment. 
These biocompatible PD solutions include neutral-pH solutions buffered with lactate or 
bicarbonate, low-GDP solutions that do not require heat sterilization, and solutions with 
icodextrin and amino acids instead of glucose as osmolar substances; all have been used in 
combination with conventional PD solutions (9). Lactate-buffered neutral PD solutions with 
low GDPs achieved using a two-chambered bag system were introduced for clinical use in 
Japan more than a decade ago. These biocompatible solutions are expected to reduce 
morphologic and functional peritoneal deterioration and the incidence rate of encapsulating 
peritoneal sclerosis, a devastating complication of PD. 
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The effectiveness of the new solutions for the prevention of peritoneal fibrosis and 
angiogenesis has been demonstrated experimentally (10–13). Several clinical studies have 
evaluated their effects (14,15), and the results of those studies indicated their usefulness in 
maintaining peritoneal integrity. However, the histologic effects of the new solutions on 
human peritoneal membrane pathology have not been evaluated. We hypothesized that use of 
neutral low-GDP solutions may improve peritoneal membrane deterioration by suppression of 
peritoneal AGE accumulation. To confirm that hypothesis, we set out in the present study to 
elucidate the histologic effects of low-GDP solutions by evaluating peritoneal biopsy samples 
obtained from patients treated solely with either conventional acidic solutions with high GDPs 
or neutral low-GDP solutions, both of which are buffered with lactate. Possible relationships 
between the use of the new PD solutions and peritoneal membrane pathology are discussed in 
terms of their clinical relevance.  
 
Materials and Methods 
Clinical findings of the PD patients 
Between 1980 and 2010, we treated 379 patients with PD and performed 205 peritoneal 
biopsies at our center. The present study enrolled 29 patients at catheter insertion (pre-PD) 
and 176 at catheter removal (post-PD). To eliminate any influence of peritonitis on peritoneal 
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histology, patients with a history of peritonitis during PD therapy were excluded from the 
study. Because neutral solutions have been used clinically only since 2002 at our center, a 
limited number of patients (n = 12) had been treated solely using such solutions (Dianeal-N: 
Baxter, Tokyo, Japan; Perisate N: JMS, Tokyo, Japan). Patients for the acidic group were 
selected from among 43 patients treated solely with acidic solution (Dianeal: Baxter; Perisate: 
JMS), who were matched with the patients of the neutral group based on age, sex, PD 
duration, and number in the group (n = 12). All patients underwent peritoneal biopsy at the 
time of PD catheter removal or when they withdrew from PD therapy. All clinical information 
was collected from medical records. Approval for the study was obtained from the Tokyo 
Women’s Medical University ethics committee. 
Clinical data included age, sex, primary cause of renal failure, PD duration, use of 
high-glucose solution (≥2.27 g/dL), residual renal function (represented by residual urine 
volume in milliliters per day), ultrafiltration volume [UFV (milliliters per day)], AGE 
accumulation score, peritoneal equilibration test (PET) category at 6 –12 months after PD 
initiation or before PD withdrawal, and administration of angiotensin converting-enzyme 
inhibitor or angiotensin II receptor blocker, statins, and vitamin D (Table 1). Patients who 
were prescribed high-glucose solution once or more daily to maintain fluid balance were 
defined as users of high-glucose solution. Ultrafiltration failure was defined as a daily UFV 
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below 400 mL. The reasons for PD withdrawal in the study cohort were PD-related problems 
such as ultrafiltration failure (acidic group: n = 8; neutral group: n = 3), desire to transfer to 
hemodialysis (acidic group: n = 2; neutral group: n = 2), renal transplantation (acidic group: n 
= 2; neutral group: n = 5), and other (neutral group: n = 2). As a control, pre-PD samples were 
selected randomly from 13 of 29 patients who underwent peritoneal biopsy at the time of PD 
catheter insertion. Among the 13 patients who provided pre-PD samples (9 men, 4 women), 
mean age was 48.2 ± 4.2 years, mean serum creatinine was 8.01 ± 0.63 mg/dL, estimated 
glomerular filtration rate was 6.96 ± 0.60 mL/min/1.73 m2, and primary causes of renal 
failure were chronic glomerulonephritis (n = 8), diabetes mellitus (n = 1), and other (n = 4). 
 
Histological evaluation for peritoneal fibrosis and vascular sclerosis 
Peritoneal biopsy specimens were cut by scalpel to approximately 1 cm×≤5 mm and 
processed using routine pathology procedures. Two pathology experts, blinded to the clinical 
backgrounds of the patients, jointly reviewed the samples to arrive at a consensus evaluation. 
The extent of peritoneal fibrosis and of vascular sclerosis was evaluated as previously 
reported (16). Briefly, for the evaluation of peritoneal fibrosis, we calculated the average 
thickness (μm) at 5 random points within the submesothelial compact zone (SMC) between 
the basal border of the surface mesothelial cells and the upper border of peritoneal adipose 
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tissue. For the evaluation of vascular sclerosis, the average ratio of lumen-to-vessel diameter 
was calculated at 5 randomly selected postcapillary venules (PCVs) with external diameters 
of 25 – 50 μm. 
 
Immunohistochemistry  
The primary antibodies used were a mouse monoclonal antibody against the AGE 
carboxymethyllysine (TransGenic, Kobe, Japan); a mouse monoclonal antibody against 
human CD31 (Dako Cytomation, Glostrup, Denmark), a marker of vascular endothelial cells; 
and a mouse monoclonal antibody against human podoplanin (AngioBio, Del Mar, CA, USA), 
a marker of lymphatic endothelial cells. The Envision+ System (Dako Cytomation) was used 
as the secondary antibody, and the antibody reaction was visualized using diaminobenzidine 
tetrahydrochloride (0.02%). Cell nuclei were counterstained with hematoxylin. To examine 
colocalization of CD31 and podoplanin in lymphatic endothelial cells, we performed double 
staining for CD31 and podoplanin using Alexa Fluor 488- or 568-labelled goat anti-mouse 
immunoglobulin G (Invitrogen, Carlsbad, CA, USA) as the secondary antibody and DAPI 
(Sigma–Aldrich, St. Louis, MO, USA) to fluorescently stain cell nuclei.  
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Evaluation of AGE accumulation 
Accumulation of AGE in the interstitium and vasculature was evaluated by a 
semi-quantitative grading method: grade 0, no AGE accumulation; grade 1, mild 
accumulation; grade 2, moderate accumulation; and grade 3, severe accumulation (17). The 
total grade score for AGE accumulation in the interstitium and vasculature were analyzed in 
association with PD duration. 
 
Evaluation of vessel density using CD31 and Podoplanin immunostaining 
The total of CD31-positive vessels and podoplanin positive lymphatic vessels located in the 
peritoneal interstitium were assessed under 200× magnification using a Leica DMD108 
digital microscope (Leica Microsystems, Wetzlar, Germany). The type of CD31-positive 
vessel (capillary or PCV) was determined based on the external diameter (in micrometers) 
along the short axis: vessels less than 15 μm in diameter were defined as capillaries; those 15 
– 100 μm in diameter were defined as PCVs. The density of each vessel type was calculated 
as the average number of vessels per area (square millimeter), assessed in 5 randomly selected 
fields of the specimen. 
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Results 
Clinical findings 
Age and PD duration did not differ significantly between the acidic- and neutral-solution 
groups (Table 1). High-glucose PD solution was used equally in both groups. The incidence 
of ultrafiltration failure was significantly higher in the acidic group. At the start of PD, neither 
residual renal function nor UFV differed between the groups. However, at the end of PD, 
residual renal function and UFV were both significantly higher in the neutral group than in the 
acidic group. At the start of PD, PET results were not significantly different; however, by the 
end of PD, the dialysate-to-plasma ratio of creatinine had become significantly higher in the 
acidic group. The groups showed no significant difference in the use of angiotensin 
converting-enzyme inhibitors or angiotensin II receptor blockers, statins, or vitamin D. 
 
Peritoneal histology  
Figure 1 shows peritoneal histology findings and results of immunohistochemistry for AGE, 
CD31, and podoplanin in representative cases from the pre-PD and in the acidic- and 
neutral-solution groups. Peritoneal specimens from the acidic group showed significant 
fibrosis in the SMC, accompanied by hyalinizing degeneration of collagen fibers. The walls of 
PCVs and capillaries are thickened and hyalinized in the acidic group [Figure 1(e)]; such 
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alterations tended to be reduced in the neutral group [Figure 1(i)]. In the acidic group 
compared with the neutral group, AGE accumulation was noted in the interstitium, and the 
vascular walls showed more intense staining [Figure 1(f) and (j) respectively]. Slight AGE 
accumulation was observed in the pre-PD peritoneal samples [Figure 1(b)]. Staining for CD31 
revealed increased vascularity in the neutral group [Figure 1(k)] compared with the pre-PD 
[Figure (c)] and acidic groups [Figure 1(g)]; however, podoplanin staining showed scant 
distribution of lymphatic vessels, without an increase in density in any group [Figure 1(d,h,l)]. 
Figure 2(a–c) shows the colocalization of CD31 and podoplanin in lymphatic endothelial cells. 
Figure 2(d) shows an example of vessel density analysis, counting the number of capillaries 
and PCVs detected by CD31 staining divided by the area of the SMC. The density of 
podoplanin-positive lymphatic capillaries was evaluated in the same manner [Figure 2(e)]. 
 
Quantitative comparison of peritoneal membrane pathology 
The average SMC thickness was significantly greater in the acidic group (482.5 ± 24.3 μm) 
than in the neutral (281.4 ± 34.4 μm) and pre-PD (201.0 ± 36.1 μm) groups, but no significant 
difference was observed between the pre-PD and neutral groups [Figure 3(a)]. The average 
ratio of lumen-to-vessel diameter in PCVs was significantly smaller in the acidic group 
(0.50±0.03) than in the pre-PD (0.87 ± 0.02) and neutral (0.86 ± 0.03) groups, but no 
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significant difference was observed between the pre-PD and neutral groups [Figure 3(b)]. In 
the acidic group, a significant correlation was observed between SMC thickness and PD 
duration [r =0.821, p < 0.0001; Figure 3(c)], and a weak correlation was observed between the 
ratio of lumen-to-vessel diameter and PD duration [r = –0.592, p = 0.00200; Figure 3(d)]; 
however, no significant correlation was observed in the neutral group [Figure 3(c,d)]. 
 
Grade of AGE accumulation was reduced in neutral solution group 
The grade of AGE accumulation in the interstitium and vascular wall was significantly higher 
in the acidic group than in the neutral and pre-PD groups. The total grade of AGE 
accumulation was also significantly higher in the acidic group than in the neutral and pre-PD 
groups (Figure 4). 
 
Peritoneal vessel density was increased in neutral solution group 
The capillary density detected by staining for CD31 was significantly higher in the neutral 
group (90.4 ±3.3/mm2) than in the acidic (30.6 ± 3.5/mm2) and pre-PD groups [51.3 ± 
3.3/mm2, Figure 5(a)]. However, the podoplanin-positive lymphatic capillary density showed 
no significant difference between groups (neutral: 12.3 ± 0.9/mm2; acidic: 11.1 ± 1.1/mm2; 
pre-PD: 10.6 ± 0.8/mm2). The density of CD31-positive capillaries was significantly and 
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positively correlated with PD duration in the neutral group (r = 0.7168, p = 0.0006) and 
negatively correlated with PD duration in the acidic group [r = –0.603, p = 0.00080; Figure 
5(b)]. 
 
PET category was associated with peritoneal AGE accumulation but not with capillary 
density  
The total grade of AGE accumulation was significantly higher in high average/ high (HA/H) 
PET category than in low/low average (L/LA) category in the acidic group[p = 0.0407, 
[Figure 6(a)]; however, the capillary density was not different between in the L/LA category 
and in the HA/H in the acidic group [Figure 6(b)]. No association between the PET category 
and the grade of AGE accumulation or capillary density was observed in the neutral group 
[Figure 6(a,b)]. These results indicated that not the capillary density, but the severity of AGE 
accumulation was associated with peritoneal hyperpermeability as determined by PET. 
 
Discussion 
Recently developed PD solutions that eliminate various bioincompatible factors such as low 
pH, lactate, glucose, and GDPs have been expected to reduce PD-related peritoneal 
deterioration. Although the precise effect of each factor is not fully understood, several 
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experimental (12,13) and clinical (14,15,18) trials have identified factors that play a causative 
role in the pathogenesis of PD-induced peritoneal damage and determined how the new 
solutions help to preserve peritoneal integrity. 
In a chronic exposure model in rats, Mortier et al. (12) demonstrated that it is mainly GDPs 
and the associated AGE formation that induces the morphology changes of peritoneal fibrosis 
and angiogenesis and the functional alterations of vascular endothelial growth factor 
production and ultrafiltration loss. Krediet et al. reported that high concentrations of lactate 
(19) and glucose (20) have greater effects on peritoneal angiogenesis, and high GDPs have a 
stronger effect on peritoneal fibrosis, probably through AGE accumulation. In a clinical trial, 
Davies et al. (18) demonstrated that high glucose exposure (also with high GDPs) was 
associated with increased peritoneal permeability and ultrafiltration loss after 5 years of PD 
treatment. With regard to the role of GDPs, Rippe et al. (14) performed a clinical trial to 
compare markers of peritoneal transport and mesothelial integrity between conventional 
high-GDP solution and low-GDP solution for 2 years. Although peritoneal transport and 
ultrafiltration were not significantly different, markers of peritoneal integrity—cancer antigen 
125 and procollagen I C-terminal peptide—were significantly higher in patients treated with 
low-GDP solution, suggesting that, compared with conventional solution, the new solution 
may cause less mesothelial and interstitial damage (14). Furthermore, in the Euro-Balance 
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Study, Williams et al. (15) demonstrated that a neutral lactate-buffered low-GDP solution 
increased effluent markers of peritoneal integrity (cancer antigen 125 and procollagen I 
C-terminal peptide) and decreased circulating AGE levels after a 12-week clinical trial, 
suggesting the promising effects of neutral and low-GDP solution as reflected in improved 
local peritoneal homeostasis and reduced AGE formation (15). In that context, the present 
study is the first to demonstrate the histologic effects of the new biocompatible solutions in 
human peritoneal specimens. The new biocompatible solutions currently available in Japan 
are neutral lactate buffered low-GDP solutions (Dianeal-N; Perisate N; Midperic: Terumo, 
Tokyo, Japan). The extent of peritoneal fibrosis and vascular wall hyalinosis were associated 
with AGE accumulation (17), and those alterations were suppressed with use of the new 
solutions containing low levels of GDPs. On the other hand, in the present study, peritoneal 
vascular density reflecting peritoneal angiogenesis was markedly increased with use of the 
new solutions, with blood and not lymphatic capillaries being affected. That result was 
confirmed by CD31 positivity and podoplanin negativity demonstrated by immunostaining of 
the endothelial cells lining the vessels. 
Peritoneal angiogenesis has been thought to be induced by PD solution (21). However, 
vascularity findings in human peritoneum after PD treatment have been controversial since 
2000. Some studies reported increased peritoneal vascular density in patients with peritoneal 
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sclerosis (22) and ultrafiltration failure (23–25); others found no significant increase in total 
vessel density in the SMC in patients receiving PD (26). 
Numata et al. (27) reported that increased peritoneal transport is associated with relative 
vascular area, but not with relative vessel number. 
In the present study, the cause of increased vascular density in the neutral group compared 
with the acidic group remains uncertain. Krediet et al. (13) proposed that high concentrations 
of glucose and lactate may be the principal factors promoting angiogenesis. 
Considering that hypothesis, we speculate that the new biocompatible solutions may 
eventually reduce the toxic effects of GDPs and may promote angiogenic responses with high 
glucose and lactate levels, which are still present in the new solutions. 
Lymphangiogenesis has been reported to occur in various diseases of kidney (28) and 
peritoneum in an experimental PD model (29), and lymphatic vessels are speculated to be 
involved in peritoneal transport and PD-related peritoneal disorders. However, the vessels that 
increased in density in the neutral group were not lymphatic vessels but blood vessels, and the 
role of lymphatic vessels in the pathogenesis of PD-related peritoneal deterioration was not 
demonstrated in the present study. 
Although increased vascular density was observed in the neutral group, it was not correlated 
with peritoneal hyperpermeability to small molecules (creatinine and glucose) as determined 
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by a PET. In contrast, the grade of AGE accumulation was significantly correlated with 
peritoneal hyperpermeability, indicating that GDPs may play a more important role in 
peritoneal hyperpermeability through AGE accumulation. Factors other than vascular 
density—such as impaired endothelial cell function or vascular integrity induced by 
GDPs—might have an important role in regulating peritoneal permeability. 
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Figure legends 
Fig. 1 Peritoneal histology and immunohistochemistry for AGE, CD31, Podoplanin in pre-PD 
(a–d), acidic (e–h) and neutral (i–l) PD groups. (a)(e)(i): Masson-trichrome staining (×200). 
(b)(f)(j): AGEs (×200), (c)(g)(k): CD31(×200). (d)(h)(l):Podoplanin (Pod) The peritoneum of 
the acidic group shows significant fibrosis in SMC accompanying hyalinizing degeneration of 
collagen fibers. AGEs were accumulated more intensely in the acidic group. CD31 staining 
revealed the increased vascularity in the neutral group, however, podoplanin staining revealed 
no increase of podoplanin positive lymphatic vessels without any differences between the 
groups. 
 
Fig. 2. Double immunostaining of CD31 and podoplanin (a-c) and examples of vessel density 
analysis by CD31 (d) and podoplanin (e). 
(a) CD31 positive vessels (green), (b) Podoplanin positive vessels (red), (c) Merge of CD31 
and podoplanin. An example of vessel density analysis: (d) CD31 positive vessel number :30 
(black circle), SMC area: 0.199mm
2
, vessel density:150.7/ mm
2
 (e) Podoplanin positive 
lymphatic vessel number : 3 (black arrow), SMC area: 0.209 mm
2
, vessel density:14.4/ mm
2
.
  
 
 
Fig. 3. Quantitative comparison of peritoneal fibrosis and vascular sclerosis and their 
correlations with PD duration. (a): SMC thickness, (b): L/V ratio, (c): correlation between 
SMC and PD duration, and (d): correlation between L/V ratio and PD duration. The SMC 
thickness was reduced and L/V ratio was increased significantly in the neutral group 
compared to the acidic group. The SMC thickness and L/V ratio were significantly correlated 
with PD duration in the acidic group, whereas no significant correlation in the neutral group.  
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Fig. 4. Comparison of peritoneal AGEs accumulation (interstitial, vascular and total). The 
grades of AGEs accumulation in interstitium and vascular wall were significantly higher in 
the acidic group than the neutral group. The total grade of AGEs accumulation was also 
significant higher in the acidic group.  
 
Fig. 5. Quantitative comparison of capillary and lymphatic vessel density, correlations 
between capillary density and PD duration. (a): The capillary density detected by CD31 was 
significantly higher in the neutral group than in the acidic group or than in the pre-PD group. 
However, no significant difference in lymphatic vessel density. (b): The density of CD31 (+) 
capillary was positively correlated with PD duration in the neutral group, on the other hand, it 
was negatively correlated with PD duration in the acidic group. 
 
Fig. 6. Comparison of AGE accumulation and capillary density between different PET 
categories; low/ low average (L/LA) category vs. high average/ high (HA/H) category.  
In acidic group, the total grade of AGE accumulation is significantly higher in HA/H category 
than in L/LA category determined by D/P Cr (a), however, the capillary density was not 
different between L/LA category and HA/H category determined by D/P Cr (b). No 
correlation was observed between PET category and AGE accumulation or capillary density 
in the neutral group (a,b). 
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Table 1. Clinical characteristics of the patients in acidic and neutral groups at the end of PD. 
 
PD, peritoneal dialysis; NS, not significant; CGN, chronic glomerulonephritis; DM, diabetes 
mellitus; UFV, ultrafiltration volume; RRF, residual renal function, represented by daily urine 
volume (mL/day); PET, peritoneal equilibration test; L, low; LA, low average; HA, high average; H, 
high; RAS, renin-angiotensin aldosteron; *1 high glucose solution contains ≥2.27 g/dL glucose; *2 
ultrafiltration failure is defined as <400ml/day of UFV.  
 
Acidic (n=12) Neutral (n=12) p-value 
Age 46.1 ± 5.3 43.0 ± 5.3 NS 
Sex (male / female) 7/5 9/3 NS 
Primary disease of renal failure 
(CGN/DM/Others) 
8/1/3 9/1/2 NS 
PD duration (month) 57.0 ± 5.97 51.9 ± 5.9 NS 
Use of high glucose solution*1 8(66.7%) 7 (58.3%) NS 
Ultrafiltration failure*2 8 (66.7%) 3 (25%) 0.0128 
RRF in the first 6-12 months of PD (mL/day) 512.5±95.2 580±95.1 NS 
RRF in the last 6-12 months of PD (mL/day) 52.5±42.7 214.1±42.7 0.0139 
UFV in the first 6-12 months of PD (mL/day) 787.5±96.1 691.7±96.1 NS 
UFV in the last 6-12 months of PD (mL/day) 224.2 ± 77.6 578.4 ± 77.5 0.0039 
PET D/P Cr in the first 6-12 months of PD 
(L/LA/HA/H) 
0.61±0.03 
(2/5/5/0) 
0.58 ± 0.03 
(3/6/2/1) 
NS 
PET D/P Cr in the last 6-12 months of PD 
(L/LA/HA/H) 
0.76 ± 0.03 
(0/3/5/4) 
0.62 ± 0.03 
(1/7/3/1) 
0.0042 
Use of RAS inhibitor 6 (50%) 8 (66.7%) NS 
Use of statin 3 (25.0%) 4 (33.3%) NS 
Use of vitamin D 7(58.3%) 7 (58.3%) NS 
